The Jonatha D Licht Lab is a renowned research facility dedicated to advancing our understanding of the molecular mechanisms underlying various diseases. Located at the University of Florida, the lab is led by Dr. Jonatha D Licht, a distinguished expert in the field of molecular biology and genetics. With a strong focus on interdisciplinary research, the lab collaborates with clinicians, scientists, and engineers to develop innovative solutions for complex medical problems.
Research Focus and Expertise
The Jonatha D Licht Lab specializes in investigating the molecular basis of cancer, with a particular emphasis on leukemia and lymphoma. The lab’s research team employs a range of cutting-edge techniques, including chromatin immunoprecipitation sequencing (ChIP-seq), RNA sequencing (RNA-seq), and CRISPR-Cas9 genome editing, to study the role of transcriptional regulators in cancer development and progression. By elucidating the underlying molecular mechanisms, the lab aims to identify novel therapeutic targets and develop more effective treatments for these devastating diseases.
Key Research Areas
The lab’s research efforts are focused on several key areas, including:
- Investigating the role of transcription factors in cancer development and progression
- Elucidating the molecular mechanisms underlying epigenetic regulation in cancer
- Developing novel therapeutic strategies for targeting cancer-specific transcriptional programs
- Exploring the intersection of cancer biology and immunology to identify innovative approaches for cancer therapy
The lab's research has been published in numerous high-impact journals, including Nature, Cell, and Cancer Cell. The team's work has also been recognized with several awards and honors, highlighting the significance and impact of their research.
| Research Area | Key Findings |
|---|---|
| Transcriptional Regulation in Cancer | Identification of novel transcription factors involved in cancer development and progression |
| Epigenetic Regulation in Cancer | Elucidation of the molecular mechanisms underlying epigenetic regulation in cancer |
| Cancer Therapy | Development of novel therapeutic strategies for targeting cancer-specific transcriptional programs |
Collaborations and Funding
The Jonatha D Licht Lab collaborates with a range of institutions and organizations, including the National Institutes of Health (NIH), the American Cancer Society, and the Leukemia & Lymphoma Society. The lab’s research is supported by numerous grants and awards, including:
- R01 grants from the NIH
- Awards from the American Cancer Society
- Grants from the Leukemia & Lymphoma Society
The lab's funding has enabled the team to pursue innovative research projects, including the development of novel therapeutic strategies for cancer treatment.
Funding Sources
The Jonatha D Licht Lab’s research is supported by a range of funding sources, including:
| Funding Source | Award Amount |
|---|---|
| National Institutes of Health (NIH) | 1.5 million</td></tr> <tr><td>American Cancer Society</td><td>500,000 |
| Leukemia & Lymphoma Society | $200,000 |
The lab's funding has been instrumental in advancing our understanding of the molecular mechanisms underlying cancer and developing innovative therapeutic strategies.
What is the focus of the Jonatha D Licht Lab’s research?
+The Jonatha D Licht Lab is focused on investigating the molecular mechanisms underlying various diseases, with a particular emphasis on cancer, including leukemia and lymphoma.
What techniques does the lab use to study cancer biology?
+The lab employs a range of cutting-edge techniques, including chromatin immunoprecipitation sequencing (ChIP-seq), RNA sequencing (RNA-seq), and CRISPR-Cas9 genome editing, to study the role of transcriptional regulators in cancer development and progression.
What are the lab’s key research areas?
+The lab’s research efforts are focused on several key areas, including investigating the role of transcription factors in cancer development and progression, elucidating the molecular mechanisms underlying epigenetic regulation in cancer, developing novel therapeutic strategies for targeting cancer-specific transcriptional programs, and exploring the intersection of cancer biology and immunology to identify innovative approaches for cancer therapy.
